These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9108412)

  • 1. CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment.
    Dunussi-Joannopoulos K; Krenger W; Weinstein HJ; Ferrara JL; Croop JM
    Blood; 1997 Apr; 89(8):2915-24. PubMed ID: 9108412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.
    Dunussi-Joannopoulos K; Dranoff G; Weinstein HJ; Ferrara JL; Bierer BE; Croop JM
    Blood; 1998 Jan; 91(1):222-30. PubMed ID: 9414288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
    Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
    Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
    Runyon K; Lee K; Zuberek K; Collins M; Leonard JP; Dunussi-Joannopoulos K
    Blood; 2001 Apr; 97(8):2420-6. PubMed ID: 11290606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia.
    LaBelle JL; Hanke CA; Blazar BR; Truitt RL
    Blood; 2002 Mar; 99(6):2146-53. PubMed ID: 11877291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.
    Dunussi-Joannopoulos K; Runyon K; Erickson J; Schaub RG; Hawley RG; Leonard JP
    Blood; 1999 Dec; 94(12):4263-73. PubMed ID: 10590071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
    Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells.
    Saudemont A; Jouy N; Hetuin D; Quesnel B
    Blood; 2005 Mar; 105(6):2428-35. PubMed ID: 15536145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML.
    Dunussi-Joannopoulos K; Weinstein HJ; Nickerson PW; Strom TB; Burakoff SJ; Croop JM; Arceci RJ
    Blood; 1996 Apr; 87(7):2938-46. PubMed ID: 8639914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.
    Dunussi-Joannopoulos K; Weinstein HJ; Arceci RJ; Croop JM
    J Pediatr Hematol Oncol; 1997; 19(6):536-40. PubMed ID: 9407942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells.
    Hirano N; Takahashi T; Takahashi T; Azuma M; Yazaki Y; Yagita H; Hirai H
    Leukemia; 1997 Apr; 11 Suppl 3():577-81. PubMed ID: 9209459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of B7-1 in mediating an immune response to myeloid leukemia cells.
    Matulonis UA; Dosiou C; Lamont C; Freeman GJ; Mauch P; Nadler LM; Griffin JD
    Blood; 1995 May; 85(9):2507-15. PubMed ID: 7537118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12.
    Joki T; Kikuchi T; Akasaki Y; Saitoh S; Abe T; Ohno T
    Int J Cancer; 1999 Aug; 82(5):714-20. PubMed ID: 10417770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.
    Saudemont A; Quesnel B
    Blood; 2004 Oct; 104(7):2124-33. PubMed ID: 15191948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.
    van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH
    Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local injections of OK432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Th1-type cytokines and CXC3 chemokines.
    Tatsugami K; Tamada K; Abe K; Harada M; Nomoto K
    Cancer Immunol Immunother; 2000 Sep; 49(7):361-8. PubMed ID: 10999462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.